The FDA has approved a process for mold insurance companies to handle the process for determining if their products are safe to use.
The process involves reviewing mold data that the company receives from a health care provider and comparing it to other mold data the company has collected from customers.
The FDA is required to approve the process in 2018, but the agency has been considering how to make it a permanent process.
The decision was announced Wednesday.
FDA said the approval process will include the testing and analysis of mold data to determine if the product is safe for use.
A study is currently being conducted to identify potential risks and benefits of the process, the FDA said.
FDA has been reviewing the mold insurance industry since it was created by the U.S. Food and Drug Administration in January 2018.
The agency said it wants to ensure that it is up to date with new information, including the recent findings about the health risks associated with mold.
FDA will be required to review all existing information submitted by manufacturers and suppliers to the agency and take into account potential risk factors in its approval process.
FDA approved the mold processing of mold insurance products in April, but it has not approved the process yet for the new process.